HomeCompareHLUBF vs PLD

HLUBF vs PLD: Dividend Comparison 2026

HLUBF yields 3.77% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $5.89M in total portfolio value
10 years
HLUBF
HLUBF
● Live price
3.77%
Share price
$4.82
Annual div
$0.18
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.3K
Annual income
$0.38
Full HLUBF calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — HLUBF vs PLD

📍 PLD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHLUBFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HLUBF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HLUBF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HLUBF
Annual income on $10K today (after 15% tax)
$320.43/yr
After 10yr DRIP, annual income (after tax)
$0.32/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $4,038,116.09/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HLUBF + PLD for your $10,000?

HLUBF: 50%PLD: 50%
100% PLD50/50100% HLUBF
Portfolio after 10yr
$2.96M
Annual income
$2,375,362.78/yr
Blended yield
80.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

HLUBF
No analyst data
Altman Z
2.1
Piotroski
5/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HLUBF buys
0
PLD buys
0
No recent congressional trades found for HLUBF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHLUBFPLD
Forward yield3.77%3.10%
Annual dividend / share$0.18$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%74.4%
Portfolio after 10y$20.3K$5.91M
Annual income after 10y$0.38$4,750,725.19
Total dividends collected$381.00$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: HLUBF vs PLD ($10,000, DRIP)

YearHLUBF PortfolioHLUBF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$10,888$188.49$11,241$540.96$353.00PLD
2$11,747$95.90$13,019$991.13$1.3KPLD
3$12,617$48.35$15,801$1,870.97$3.2KPLD
4$13,525$24.27$20,609$3,701.21$7.1KPLD
5$14,484$12.15$29,919$7,867.97$15.4KPLD
6$15,503$6.08$50,631$18,617.74$35.1KPLD
7$16,592$3.04$105,528$51,352.20$88.9KPLD
8$17,755$1.52$287,364$174,449.42$269.6KPLD
9$18,998$0.76$1,081,760$774,280.77$1.06MPLD
10$20,329$0.38$5,908,209$4,750,725.19$5.89MPLD

HLUBF vs PLD: Complete Analysis 2026

HLUBFStock

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

Full HLUBF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this HLUBF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HLUBF vs SCHDHLUBF vs JEPIHLUBF vs OHLUBF vs KOHLUBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.